|
|
||||||||
Organizing their review around a scene from the 1939 movie "The Wizard of Oz," Shaner et al. offer a model procedure for communicating the diagnosis of death by neurologic criteria. An unequivocal, straightforward approach provides a message better understood by family and staff. Confusion and inconsistent decision-making is reduced with adherence to policy.
see page 1683
Daily opioid therapy for intractable headache: Long-term observations
Saper et al. studied treatment response, compliance, and other variables in 160 patients placed on daily opioid therapy for intractable head pain. They found that only a quarter of the patients showed sustained improvement over 3 to 5 years; many of these failed to improve in functional activity or non-opioid medication reduction. Medication noncompliance/misuse was identified in up to 50% of patients, despite intense supervision of treatment.
see page 1687
Narcotic overuse for acute migraine headache treatment
Narcotics are not considered first line therapy for migraine headache. The Colman et al. study of five linked Emergency Departments in one Canadian region suggests that initial treatment with narcotics remains common (60%); however, practice variation is considerable (site ranges: 35 to 78%). Factors associated with narcotic use are predictable and suggest that a concerted effort to replace their use is indicated.
see page 1695
Opioid therapy and headache: A cause and a cure
The editorial accompanying these two articles by Richard B. Lipton and Marcelo E. Bigal notes that the role of opioids in headache treatment is complex because of the closely related issues of medication overuse headache and transformed migraineopioids are a risk factor for medication overuse headache and transformed migraine. Taken together, the Colman et al. and Saper et al. studies support a diminished role for opioids as an acute treatment of migraine and cautious expansion of their use in the long-term preventive treatment of otherwise intractable headache. Given the availability of better treatment options (triptans, dihydroergotamine, neuroleptics, or nonsteroidal anti-inflammatory agents) it is surprising that nearly 60% of migraine sufferers presenting to the Emergency Departments of five Canadian hospitals received narcotics as their first treatment.
see page 1662
Improved developmental outcomes after hemispherectomy
|
see page 1712
The accompanying editorial by Michael Duchowny traces the history of hemispherectomy from its first introduction by Dandy in 1928 through the successive refinements of technique which have made it an important treatment modality for uncontrolled epilepsy. He notes that the Jonas et al. experience is the largest reported and that they make major strides in defining the criteria that may soon make hemispherectomy an early as opposed to a last resort treatment for medication-refractory epilepsy.
see page 1664
Cognition in temporal lobe epilepsy
|
see page 1736
Elevated alpha-synuclein marks Parkinson disease in rare family
|
-synuclein protein in the blood of patients with an
-synuclein gene triplication and accumulation of insoluble, aggregated
-synuclein in brain. This suggests that
-synuclein aggregation and deposition are important in the cause of PD.
see page 1835
Intravenous r-TPA in vertebrobasilar ischemia
The observational study by Montavont et al. reports 18 patients with vertebrobasilar ischemia who were treated by IV r-TPA after a mean delay 5 ± 3.6 hours (baseline NIHSS score 17 ± 4). At 3 months, 10 patients were independent.
see page 1854
L-2 hydroxyglutaric aciduria (L-2-OPHGA) and brain tumors
|
see page 1882
| ||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |